WG
ORIC icon

Winton Group’s Oric Pharmaceuticals ORIC Stock Holding History

Winton Group’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$899K Buy
+83,000
New +$753K 0.03% 539

Other funds holding ORIC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Winton Group's ORIC Position: Q2 2026 in Review

Winton Group opened a new position in Oric Pharmaceuticals (ORIC) in Q2 2026: 83,000 shares worth $899K. The stake represents 0.03% of the portfolio and ranks #539 among its holdings.

39 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Winton Group held 83,000 shares of Oric Pharmaceuticals worth $899K as of Q2 2026.
  • Oric Pharmaceuticals was a new Winton Group position in Q2 2026.
  • Oric Pharmaceuticals made up 0.03% of Winton Group's portfolio in Q2 2026, its #539 holding.
  • 39 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.